Yahoo•2026-04-22
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal HyperplasiaNBIX — Neurocrine Biosciences Inc
NASDAQ · Biotechnology · Biotechnology
$130.22-15.85%Market cap13.21B
- Latest Close
- $130.22
- 30-Day Move
- -15.9%
- Market Cap
- $13.2B
- Shares Outstanding
- 100,360,000
- P/E Ratio
- 27.6
- P/B Ratio
- 4.35
Analyst consensus: Buy · 36 analysts
NASDAQ:NBIXBiotechnology / BiotechnologyDelayed public snapshot
Neurocrine Biosciences Inc
A read-only Alphactor snapshot forNeurocrine Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$130.22
30-Day Move
-15.9%
Market Cap
$13.2B
Shares Outstanding
100,360,000
P/E Ratio
27.6
P/B Ratio
4.35
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$130.22
-15.9%last 90 delayed daily bars
Market cap$13.2B
90D High
$156.46
90D Low
$122.14
Avg Volume
1,139,482
What stands out
Gross margin is running at 98.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 16.7%, useful for comparing NBIX against peers in Biotechnology.
NBIX is down 15.9% over the last 30 trading days shown on this page.
Latest operating income is $637M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$167.05
Rule of 40
47.6%
Fundamentals snapshot
Latest Close
$130.22
30-Day Move
-15.9%
Market Cap
$13.2B
Shares Outstanding
100,360,000
P/E Ratio
27.6
P/B Ratio
4.35
ROE
14.7%
ROA
10.3%
Gross Margin
98.2%
Operating Margin
21.6%
Net Margin
16.7%
Debt / Equity
0
Current Ratio
3.39
Latest Revenue
$2.9B
Financial statement snapshot
Revenue
$2.9B
Gross Profit
$2.8B
Operating Income
$637M
Net Income
$479M
Gross Margin
9818.0%
Net Margin
1673.0%
Current Ratio
3.39
Debt / Equity
0.00
Valuation snapshot
Fair Value
$167.05
Upside / Downside
+28.3%
Signal
Undervalued
Implied Growth
3.0%
DCF
$295.97
EPV
$59.69
EV/Rev
$145.48
Growth Assumption
24.3%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$749M
Valuation spread
Current Price
$130.22
Composite Fair Value
$167.05
DCF
$295.97
EPV
$59.69
EV/Rev
$145.48
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
7.42
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
1.64x
Rule of 40
47.6%
Strong
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.5B | $249M | $155M | $323M |
| 2023-12-31 | $1.9B | $395M | $250M | $362M |
| 2024-12-31 | $2.4B | $583M | $341M | $557M |
| 2025-12-31 | $2.9B | $637M | $479M | $749M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Yahoo•2026-04-21
3 Reasons Growth Investors Will Love Neurocrine (NBIX)Yahoo•2026-04-21
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a BetChartMill•2026-04-17
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical SetupYahoo•2026-04-17
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XRAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-04 | ABERNETHY MATT | G | 2,249 | $0.00 |
| 2026-02-20 | Onyia Jude | G | 3,110 | $0.00 |
| 2026-02-13 | Delaet Ingrid | A | 5,479 | $0.00 |
| 2026-02-13 | Delaet Ingrid | A | 31,234 | $0.00 |
| 2026-02-13 | Delaet Ingrid | M | 1,359 | $0.00 |
| 2026-02-13 | Delaet Ingrid | M | 1,401 | $0.00 |
| 2026-02-13 | Delaet Ingrid | F | 10,755 | $124.12 |
| 2026-02-13 | Delaet Ingrid | A | 19,935 | $0.00 |
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-05-15
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
BlackRock
Filed 2024-08-13
$2.0B
--
Vanguard Group
Filed 2026-01-29
$1.4B
-0.1%
Renaissance Technologies
Filed 2025-11-13
$339M
+2.2%
Geode Capital Management
Filed 2026-02-09
$291M
+1.7%
Analyst consensus?
Rating(?)
4.22
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
36
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.